Zobrazeno 1 - 10
of 60
pro vyhledávání: ''
Autor:
Masako Sato, Hidetoshi Kawaguchi, Satoshi Morita, Makiko Mizutani, Yoshie Hasegawa, Ken-ichi Watanabe, Yasuaki Sagara, Fumikata Hara, Takashi Morimoto, Takahiro Nakayama, Norikazu Masuda, Mitsuya Itoh, Shoichiro Ohtani, Nobuki Matsunami, Kenji Higaki, Masato Takahashi, Tetsuhiro Yoshinami
Publikováno v:
Breast Cancer (Tokyo, Japan)
Background This study aimed to investigate whether schedule modification is safe and effective in patients intolerant to the standard eribulin dose and schedule. Methods Patients with metastatic breast cancer (MBC) treated with both anthracycline and
Autor:
Hanne Frydenberg, Gro F. Bertheussen, Vidar Gordon Flote, Hartmut Schäfer, Inger Thune, Steinar Lundgren, Ellen Schlichting, Torfinn Støve Madssen, Erik Wist, Tone Frost Bathen, Riyas Vettukattil, Guro F. Giskeødegård, Jon Lømo, Hans E. Fjøsne
Publikováno v:
British Journal of Cancer
Background Breast cancer treatment has metabolic side effects, potentially affecting risk of cardiovascular disease (CVD) and recurrence. We aimed to compare alterations in serum metabolites and lipoproteins during treatment between recipients and no
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::160be7e8db63fd6c4a60bb91080f4b51
https://hdl.handle.net/11250/2592790
https://hdl.handle.net/11250/2592790
Autor:
C. Rose, R Leonard, M Tubiana-Hulin, Denis Lacombe, J Vinholes, J Wildiers, J Michel, Robert E. Coleman, J Nortier, J. Ford, F. Mignolet, P Bastit
Publikováno v:
British Journal of Cancer
This study was designed to evaluate new bone resorption and tumour markers as possible alternatives to serial plain radiographs for the assessment of response to treatment. Thirty-seven patients with newly diagnosed bone metastases from breast cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::76f16dd46c0774b038d4bedfedc3bf7f
Publikováno v:
Cancer Immunology, Immunotherapy
To examine the relationship between cytotoxic T lymphocyte antigen 4 (CTLA-4) expression and breast cancer prognosis, CTLA-4 expression was immunohistochemically detected in paraffin-embedded specimens of primary tumors from 130 patients with breast
Autor:
Oumar Camara, Carola Rabenstein, Cornelia Jörke, Klaus Hoeffken, Ingo B. Runnebaum, Katharina Pachmann, Anne Egbe, U. Hammer
Publikováno v:
Journal of Cancer Research and Clinical Oncology. 135(4):643-647
In breast cancers, the gene for the growth factor receptor HER2 can be amplified leading to increased aggressiveness and metastasis formation. The monoclonal antibody trastuzumab prolongs relapse-free survival highly significantly but eventually many
Autor:
Sally Tan, Pasi A. Jänne, John J. Wright, Katherine Larrabee, Hao Guo, Eric P. Winer, Sara M. Tolaney, Eliezer M. Van Allen, Elena Ivanova, Ian E. Krop, Beth Overmoyer, William H. Barry, Jane E. Brock, Geoffrey I. Shapiro, Cloud P. Paweletz, Nikhil Wagle
Publikováno v:
Investigational New Drugs
SummaryBackground MET expression and activation appear to be important for initiation and progression of triple-negative breast cancer. Tivantinib (ARQ 197) is an orally administered agent that targets MET, although recent preclinical data suggests t
Autor:
Mel Fox, Gary C. Starling, Mian Su, Sonia Tanlimco, Debra Chao, Shiming Ye, Donghee Choi, Johnny Yin, Lisa Durkin, Patricia Culp, Yongke Zhang, Eric D. Hsi, Mien Sho, Han Kim
Publikováno v:
Journal of Cancer Research and Clinical Oncology
Background The receptor for the cytokine TWEAK (TweakR) is a cell surface member of the tumor necrosis factor receptor superfamily with diverse biological roles. TNFRSF family members are appealing therapeutic targets in oncology due to their aberran
Autor:
Roy Nitulescu, Tripthi Kamath, Marjolaine Gauthier-Loiselle, Annie Guerin, Anthony Masaquel, Kenneth More, Raluca Ionescu-Ittu, Nicholas Sicignano, Brian Barnett, Christopher Gallagher, Elizabeth Butts, Eric Q. Wu
Publikováno v:
Breast Cancer Research and Treatment
Trastuzumab reduces the risk of relapse in women with HER2-positive non-metastatic breast cancer, but little information exists on the timing of trastuzumab initiation. The study investigated the impact of delaying the initiation of adjuvant trastuzu
Autor:
Ahmad Awada, A. Douglas Laird, Geoffrey I. Shapiro, Patrick Schöffski, Sara M. Tolaney, Hovav Nechushtan, Chris A. Yasenchak, Eric P. Winer, Bridget O’Keeffe, I. G. Ron
Publikováno v:
Breast Cancer Research and Treatment
Breast cancer research and treatment, 160 (2
Breast cancer research and treatment, 160 (2
Purpose: Cabozantinib (XL184), a multi-targeted oral tyrosine kinase inhibitor with activity against MET, VEGFR2, AXL, and other tyrosine kinases, was assessed in a cohort of metastatic breast cancer (MBC) patients in a phase II randomized discontinu
Autor:
Hans-Peter Goertz, Amy Pugh, Juan Marcos Gonzalez, Vincent Antao, Christine Poulos, Eleftherios P. Mamounas
Publikováno v:
Annals of Surgical Oncology
Background This study aimed to assess the influence of disease- and patient-related factors on surgeons’ decisions to refer patients with early-stage breast cancer (EBC) for neoadjuvant systemic therapy (NST). Methods An online survey of United Sta